Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson’s disease dementia

Several studies have demonstrated clinical benefits of sustained cholinesterase inhibition with rivastigmine in Alzheimer’s disease (AD) and Parkinson’s disease dementia (PDD). Unlike donepezil and galantamine that selectively inhibit acetylcholinesterase (AChE; EC 3.1.1.7), rivastigmine is a unique...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Interv Aging
Autors principals: Kandiah, Nagaendran, Pai, Ming-Chyi, Senanarong, Vorapun, Looi, Irene, Ampil, Encarnita, Park, Kyung Won, Karanam, Ananda Krishna, Christopher, Stephen
Format: Artigo
Idioma:Inglês
Publicat: Dove Medical Press 2017
Matèries:
Review
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5402908/
https://ncbi.nlm.nih.gov/pubmed/28458525
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CIA.S129145
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars